研究肝細(xì)胞肝癌（HCC）患者血清高遷移率族蛋白B1（HMGB1）水平變化及臨床意義

[摘要] 目的 分析研究肝細(xì)胞肝癌（HCC）患者血清高遷移率組蛋白B1（HMGB1）水平變化情況，并探討其臨床意義。方法 方便選取該院2015年3月—2016年3月收治的肝細(xì)胞肝癌患者50例作為研究對(duì)象，分別采用酶聯(lián)免疫法、電化學(xué)發(fā)光法對(duì)其血清HMGB1及AFP的水平進(jìn)行測(cè)定，另取同期收治的肝臟良性病變患者和接受體檢的正常人各50例作為對(duì)照，行相同檢測(cè)，比較3組患者兩項(xiàng)指標(biāo)檢測(cè)結(jié)果之間的差異。同時(shí)觀察不同TNM分期肝細(xì)胞肝癌組患者HMGB1和AFP的檢測(cè)結(jié)果，并分析其相關(guān)性。 結(jié)果 受檢者的血清HMGB1、AFP水平比較，均有肝細(xì)胞肝癌組患者顯著高于肝臟良性病變組患者，顯著高于健康對(duì)照組的情況，且每?jī)山M的比較均差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。隨著分期的增加，其HMGB1和AFP水平均不斷升高，各組患者之間的檢測(cè)結(jié)果差異有統(tǒng)計(jì)學(xué)意義（P<0.05），且HMGB1和AFP的檢測(cè)結(jié)果呈顯著正相關(guān)（r=0.701，P<0.05）。 結(jié)論 肝細(xì)胞肝癌患者的HMGB1水平有著升高的表現(xiàn)，且隨著病情進(jìn)展，檢測(cè)水平也不斷升高，其有望成為診斷肝細(xì)胞肝癌的敏感指標(biāo)。

[關(guān)鍵詞] 肝細(xì)胞肝癌；血清高遷移率組蛋白B1；診斷；臨床價(jià)值

[中圖分類號(hào)] R735 [文獻(xiàn)標(biāo)識(shí)碼] A [文章編號(hào)] 1674-0742（2016）11（c）-0026-03

[Abstract] Objective To investigate the clinical value of the variation of serum high mobility group protein B1 （HMGB1） in patients with hepatocellular carcinoma （HCC）. Methods Random selection 50 cases of hepatocellular carcinoma in our hospital from March 2015 to March 2016 were selected， and the serum levels of HMGB1 and AFP were measured by enzyme-linked immunosorbent assay and electrochemical luminescence method. Another 50 cases of normal physical in the same period were chosen as the control group and given the same test.The level of the two indicators in the three groups were compared. And the detection results of HMGB1 and AFP in patients with hepatocellular carcinoma in different TNM stages were observed， and their correlation was analyzed. Results The contents of serum HMGB1， AFP in hepatocellular carcinoma patients were significantly higher than those of benign liver disease group， and those in both the above groups were significantly higher than that of normal controls （P < 0.05）. the HMGB1 and AFP levels increased with the increase of stage， with significant differences （P < 0.05）， and the test results of HMGB1 and AFP showed significant positive correlation （r=0.701，P < 0.05）.Conclusion The level of HMGB1 in patients with hepatocellular carcinoma increased according to the progress of the disease， which is expected to be a sensitive indicator for diagnosis of hepatocellular carcinoma.

[Key words] Hepatocellular carcinoma；Serum high mobility group protein B1 （HMGB1）；Diagnosis；Clinical value

肝細(xì)胞肝癌是十大惡性腫瘤之一，不僅嚴(yán)重危害患者的身體健康和生命安全，而且治療的預(yù)后效果也不十分理想[1]?？紤]到肝細(xì)胞肝癌的發(fā)病是多種因素共同作用的結(jié)果，做好早期診斷意義重大。該文就該院2015年3月—2016年3月收治的肝細(xì)胞肝癌患者50例作為研究對(duì)象，分析研究血清高遷移率組蛋白B1檢測(cè)在臨床診斷中的應(yīng)用價(jià)值，現(xiàn)報(bào)道如下?！?br>